MacroGenics(MGNX) - 2023 Q1 - Earnings Call Presentation

18 CONFIDENTIAL | --- | --- | |-------------------------------------|-------| | | | | Stratification Factors: | | | • Disease Location | | | (bone only vs. visceral) • Region | | PARCE SENICS MGD024 is investigational and has not yet been approved for marketing by any regulatory authority MACRO GENICS MGD024 MGD024: Favorable Cytokine Profile, Encouraging Combination Activity (in vivo) Improved Tolerability vs. Wild Type (WT) in Cynos 21 Preclinical data presented at ASH 2021 Interleukin-6 MGD024 Enhances A ...